Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide
Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
1. A mixture of compounds of formulae:
or pharmaceutically acceptable salts thereof.
2. The mixture of claim 1 , wherein compounds P and Q, or pharmaceutically acceptable salts thereof, are present in a 1:1 mixture.
3. The mixture of claim 1 , wherein compound P, or a pharmaceutically acceptable salt thereof, is present in an amount greater than 90%.
4. The mixture of claim 1 , wherein compound P, or a pharmaceutically acceptable salt thereof, is present in an amount greater than 95%.
5. The mixture of claim 1 , wherein compound P, or a pharmaceutically acceptable salt thereof, is present in an amount greater than 98%.
6. The mixture of claim 1 , wherein compound Q, or a pharmaceutically acceptable salt thereof, is present in an amount greater than 90%.
7. The mixture of claim 1 , wherein compound Q, or a pharmaceutically acceptable salt thereof, is present in an amount greater than 95%.
8. The mixture of claim 1 , wherein compound Q, or a pharmaceutically acceptable salt thereof, is present in an amount greater than 98%.
9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a mixture according to any of claims 1 to 8 .
10. A tablet, capsule, troche, dispersion, suspension, solution, or patch according to claim 9 .